Patent application number | Description | Published |
20100178253 | PEPTIDE IMAGING AGENTS - The present invention relates to labelled cMet binding peptides suitable for optical imaging in vivo. The peptides are labelled with a benzopyrylium dye suitable for imaging in the red to near-infrared region. Also disclosed are pharmaceutical compositions and kits, as well as in vivo imaging methods, especially of use in the detection, staging, diagnosis, monitoring of disease progression or monitoring of treatment of colorectal cancer (CRC). | 07-15-2010 |
20100196282 | OPTICAL IMAGING AGENTS - The present invention relates to imaging agents suitable for in vivo optical imaging, which comprise conjugates of benzopyrylium dyes with biological targeting moieties, such as peptides Also disclosed are pharmaceutical compositions and kits, as well as in vivo imaging methods. | 08-05-2010 |
20110189089 | RADIOFLUORINATION - The present invention relates to | 08-04-2011 |
20110280806 | DYE CONJUGATE IMAGING AGENTS - The present invention relates to imaging agents suitable for in vivo optical imaging, which comprise conjugates of dihydrocarbazolium dyes with biological targeting moieties, such as peptides. Also disclosed are pharmaceutical compositions and kits, as well as in vivo imaging methods. The dihydrocarbazolium dyes are functionalised with water solubilising groups and have functional groups which facilitate conjugation to biological targeting moieties. | 11-17-2011 |
20120251447 | RADIOIODINATED TROPANE DERIVATIVES - The present invention provides novel radio iodinated tropanes incorporating triazole or isoxazole rings. Also provided are methods of preparation of said tropanes from functionalised tropane precursors, using click cycloaddition chemistry, as well as radiopharmaceutical compositions comprising such radio iodinated tropanes. The invention also provides in vivo imaging methods using the radio iodinated tropanes. | 10-04-2012 |
20130064770 | RADIOLABELED COMPOUNDS AND METHODS THEREOF - The present invention relates to radiodiagnostic compounds, methods of making those compounds, and methods of use thereof as imaging agents for preferably a HA serotonin 5-HT1A receptor for use in PET or SPECT, preferably PET. Compositions comprising an imaging-effective amount of radiolabeled compounds are also disclosed. The present invention also relates to non-radiolabeled compounds, methods of making those compounds, and methods of use thereof to treat various neurological and/or psychiatric disorders. | 03-14-2013 |
20130225829 | FLUORINATION PROCESS - The invention relates to a process for preparation of a compound of formula (I): | 08-29-2013 |
20130272960 | RADIOIODINATED FATTY ACIDS - The present invention provides novel radioiodinated fatty acids. Also provided are methods of preparation of said radioiodinated fatty acids from non-radioactive precursors, as well as radiopharmaceutical compositions comprising such radioiodinated fatty acids. The invention also provides in vivo imaging methods using the radioiodinated fatty acids. | 10-17-2013 |
20130272961 | RADIOIODINATED GUANIDINES - The present invention provides novel radioiodinated guanidines. Also provided are methods of preparation of said radioiodinated guanidines from non-radioactive precursors, as well as radiopharmaceutical compositions comprising such radioiodinated guanidines. The invention also provides in vivo imaging methods using the radioiodinated guanidines. | 10-17-2013 |
20130315824 | RADIOIODINATION METHOD - The present invention provides a novel method of labelling biological targeting molecules (BTMs) of interest with radioiodine. Also provided are functionalised BTMs useful in the method, as well as methods of preparing such functionalised BTMs under mild conditions. | 11-28-2013 |
20140243555 | METHOD FOR THE SYNTHESIS OF 18F-LABELLED MOLECULES - The present invention provides a method for the synthesis of 18F-labelled biomolecules, which is amenable to automation. The present invention also provides a cassette for automating the method of the invention. The method of the present invention provides numerous advantages over the prior art methods. One less purification step is required as compared with known methods. Also, in a preferred embodiment, one less reagent is required as a particular reagent is employed in two different steps. The chemistry process is thereby simplified, the cost of goods is reduced and the burden of validation and documentation of reagents required for GMP clinical production is minimised. | 08-28-2014 |